Physician profile
Lisa Buchanon
NPI 1710586623
$1,143.23
in general payments reported to CMS, 2019-2025
17 companies · $826 in 2025
The $826 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.96 · 2024: $298 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $282.41 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $172.90 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.88 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.08 | 2024-2025 | Xifaxan |
| Pfizer INC. | $75.41 | 2024-2025 | |
| Novo Nordisk INC | $72.46 | 2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $50.37 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $49.08 | 2025 | Fanapt |
| Exact Sciences Corporation | $48.75 | 2024-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $41.58 | 2025 | Gemtesa |
| Amgen INC. | $36.98 | 2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $31.75 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $22.37 | 2025 | |
| Qiagen, LLC | $19.96 | 2022 | |
| Lilly USA, LLC | $19.27 | 2025 | Mounjaro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.37 | 2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $16.61 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Buchanon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.